Macugen (Pegaptanib Sodium)

DRUG3 trials

Sponsors

Eyetech Pharmaceuticals, Retina Institute of Hawaii

Conditions

Age-Related Macular DegenerationDiabetic Macular EdemaPDR

Phase 1

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

CompletedNCT01487070

Retina Institute of HawaiiPDR

Start: 2011-04-30End: 2011-07-31Updated: 2011-12-07

Phase 4

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

TerminatedNCT00134667

Eyetech PharmaceuticalsAge-Related Macular Degeneration

Start: 2005-03-31End: 2008-10-31Target: 360Updated: 2007-01-15

Unknown Phase

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Retina Institute of HawaiiDiabetic Macular Edema

Updated: 2011-12-07